New inhaled psychedelic drug GH001 enters first human safety trial
Knowledge-focused
Not yet recruiting
This early-stage trial will give a single inhaled dose of GH001 (5-MeO-DMT) to 12 healthy adults. Researchers will measure how the drug moves through the body and check for any side effects. The goal is to gather basic safety information needed before testing the drug in people w…
Phase: PHASE1 • Sponsor: GH Research Ireland Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC